Company intelligence / Profile preview
BrightPath Biotherapeutics Co., Ltd.
Chiyoda-ku Tokyo City/Kojimachi Central Building HQ, Tokyo Prefecture, Japanbrightpathbio.com ↗
- Ownership
- Private
- Employees
- ~24
- Development stage
- Other
01
Overview
BrightPath Biotherapeutics develops novel immunotherapies against cancer using proprietary platforms such as iPSC-derived natural killer T-cell therapies. The company has demonstrated initial safety and early activity in a first-in-human trial of unmodified iPS-NKT cells for head and neck cancer. Its pipeline includes peptide vaccines, gene-modified cell therapies like HER2-targeted CAR-iNKT/CAR-T products now entering or preparing for early-phase trials, as well as antibody-based immunomodulators. Early results show promise in tumor control with durable responses in preclinical models; clinical data are emerging from ongoing investigator-led studies at leading Japanese institutions.[1][7]
- Therapeutic areas
- Oncology
- Modalities
- Cell therapy (iPSC-derived NKT cells, CAR-NKT, CAR-T)Cancer peptide vaccinesMonoclonal antibodies and bispecific antibodies targeting immune checkpoints/modulators[1][6][8]
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
– Cellistic (process development/manufacturing collaboration on allogeneic iPS-NKT/CAR-T platform) [5]
Beyond the preview
Go deeper on BrightPath Biotherapeutics Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BrightPath Biotherapeutics Co., Ltd..